Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
Introduction The success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (...
Saved in:
| Main Authors: | Mads Rosenkilde, Bente Merete Stallknecht, Simon Birk Kjær Jensen, Julie Rehné Lundgren, Charlotte Janus, Christian Rimer Juhl, Lisa Møller Olsen, Sten Madsbad, Signe Sørensen Torekov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/11/e031431.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01) -
Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
by: Matthias Ploug Larsen, et al.
Published: (2017-01-01) -
Proteomics reveals the effects of sustained weight loss on the human plasma proteome
by: Philipp E Geyer, et al.
Published: (2016-12-01) -
The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson’s disease with diabetes co-morbidity
by: Xiaomin Zhang, et al.
Published: (2025-06-01) -
Estimating the budget impact of innovative pharmacological treatments for patients with type 2 diabetes mellitus in Italy: the case of liraglutide (GLP-1).
by: Stefano Capri, et al.
Published: (2015-06-01)